Sign in11 stories
The application, based on the Phase III SAFFRON trial, targets patients who progressed on EGFR-TKI therapy with MET overexpression or amplification.
SEC filing (2)
Longer follow-up in western patients on ivonescimab plus chemotherapy matched survival gains seen earlier in Asian patients, with no new safety signals.
SEC filing
Akeso's HARMONi-GI1 trial in China showed ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in advanced biliary tract cancer.
SEC filing
HARMONi-GU1 will test ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin in untreated advanced urothelial carcinoma, with site activations planned by Q4 2026.
SEC filing
Arcus added three new clinical collaborations for its HIF-2α inhibitor casdatifan and said cash runway extends to at least the second half of 2028.
SEC filing
Summit Therapeutics posted $690.7 million in cash at quarter end and highlighted updated HARMONi survival data ahead of a November 14, 2026 FDA decision on ivonescimab.
SEC filing (2)
The oncology company opened a new at-the-market equity program with J.P. Morgan while warning it lacks enough working capital for the next year.
SEC filing
The company signed a distribution agreement with J.P. Morgan Securities allowing it to sell shares over time but carries no obligation to do so.
SEC filing